http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
" MULTINEURON " NEURAL SIMULATOR AND ITS MEDICAL APPLICATIONS
S. E. Gilev,A. N. Gorban,D. A. Kochenov,Ye. M. Mirkes,S. E. Golovenkin,S. A. Dogadin,E. V. Maslennikova,G. V. Matyushin,K. G. Nozdrachev,D. A. Rossiev,V. A. Shulman,A. A. Savchenko 대한전자공학회 1994 ICONIP : International Conference On Neural Inform Vol.3 No.2
" Multineuron " Neural Simulator and Its Medical Applications
Alexander N. Gorban,S. E. Gliev,D. A. Kochenov,Ye. M. Mirkes,S. E. Golovenkin,S. A. Dogadin,K. G. Nazdrachev,E. V. Maslennikova,G. V. Matyushin,D. A. Rossiev,V. A. Shulman,A. A. Savchenko 대한전자공학회 1994 ICONIP : International Conference On Neural Inform Vol.3 No.1
( Welzel Tm ),( Isakov V ),( Trinh R ),( Streinu-cercel A ),( Dufour J-f ),( Marinho Rt ),( Moreno C ),( Liu L ),( Xie W ),( Tatsch F ),( Shulman Ns ),( Craxi A ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Ombitasvir (OBV), paritaprevir with the pharmacokinetic enhancer ritonavir (PTV/r), and dasabuvir (DSV) without ribavirin (RBV) has demonstrated sustained virologic response at 12 weeks post-treatment (SVR12) rates of 99-100% in HCV GT1b-infected patients without cirrhosis. In GT1b-infected patients with cirrhosis, OBV/PTV/r + DSV with RBV for 12 weeks achieved an SVR12 rate of 98.5%. Regimens with RBV are associated with higher rates of adverse events (AEs), primarily anaemia, and a higher pill burden. This post hoc, pooled analysis from 5 Phase 3/3b trials investigated the efficacy and safety of the RBV-free, 12-week regimen of OBV/PTV/r + DSV among HCV GT1b-infected patients with or without compensated cirrhosis. Methods: Data for patients treated without RBV in 5 trials (GT1b-infected patients with cirrhosis: TURQUOISE-III; GT1b-infected patients without cirrhosis: PEARL-II, PEARL-III, TOPAZ-II, MALACHITE-I) were pooled and patients were characterised by the presence or absence of compensated cirrhosis at baseline. Treatment-naive and pegylated interferon/RBV-experienced patients were included in the analysis population. Efficacy and safety were assessed in all patients. Comparisons of safety outcomes between groups were analysed using Fisher’s exact test. Results: The pooled analysis included 60 patients with cirrhosis and 521 patients without cirrhosis: 62% and 48% were male, 87% and 91% were white, and 45% and 74% were treatment-naive, respectively. SVR12 with OBV/PTV/r + DSV for 12 weeks was 100% (60/60) and 99% (515/521) in patients with and without cirrhosis, respectively. Three patients without cirrhosis experienced virologic failure. Treatment-emergent AEs and laboratory abnormalities are provided in the following table. Conclusions: In HCV GT1b-infected patients, SVR12 rates with the RBV-free, 12-week regimen of OBV/PTV/r + DSV were very high in patients with and without compensated cirrhosis (100% and 99%). Treatment was well tolerated, with no discontinuations due to an AE, and there were low rates of serious AEs and grade 3/4 laboratory abnormalities.